Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-01
2009-12-29
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010, C514S265100, C514S275000, C514S300000, C514S301000, C514S303000, C514S310000, C514S317000, C514S320000, C514S343000, C514S357000, C514S364000, C514S365000, C514S366000, C514S406000, C514S422000, C514S423000, C514S616000, C544S111000, C544S343000, C544S344000, C544S350000, C544S386000, C544S405000, C546S122000, C546S192000, C546S268100, C548S153000, C548S179000, C548S203000, C548S235000, C548S247000, C548S309700, C548S364100, C548S453000, C548S491000, C548S530000, C548S953000, C549S059000, C549S
Reexamination Certificate
active
07638513
ABSTRACT:
This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.
REFERENCES:
patent: 5618842 (1997-04-01), Della Valle et al.
patent: 6344457 (2002-02-01), Jeanpetit et al.
patent: 6495565 (2002-12-01), Duan et al.
patent: 6534491 (2003-03-01), Levin et al.
patent: 6677355 (2004-01-01), Conrad et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 2006/0252778 (2006-11-01), Guo et al.
patent: 2007/0129378 (2007-06-01), Siddiqui et al.
patent: 2007/0167426 (2007-07-01), Siddiqui et al.
patent: 1484601 (1967-06-01), None
patent: WO01/21661 (2001-03-01), None
patent: WO01/44179 (2001-06-01), None
patent: WO03/076461 (2001-09-01), None
patent: WO01/77075 (2001-10-01), None
patent: WO02/102791 (2002-12-01), None
patent: WO2005/019194 (2005-03-01), None
patent: WO2005/121130 (2005-12-01), None
Allenmark, S., et al.; “Chiral selectors based on C2-symmetric Dicarboxylic acids”; Tetrahedron; 11(17): 3527-3534 (2000).
Behr, Jean-Bernard, et al.; “Design synthesis and biological evaluation of hetaryl-nucleoside derivatives as inhibitors of chitin synthase”; Bioorganic & Medicinal Chemistry Letters; 13(10):1713-1716 (2003).
Coggins, J.R., et al.; “Use of Dimethyl Suberimidate and Novel Perodate-Cleavable Bis(imido esters) to Study the Quaternary Structure of the Pyruvate Dehydrogenase Multienzyme Complex ofEscherichia coli”; Biochemistry; 15(12):2527-2533. (1976).
D'Ianni, J.D., et al.; “Hydrogenation of Hydroxyamides”; Journal of the American Chemical Society; 61:1675-1681(1939).
Einhorn, et al.; CAS Accession No. 1908:12246.
Frankland, et al.; CAS Accession No. 1907:2912.
Frankland, Edward Percy; “CCLXIX—The Reaction Between Benzylamine and the Dibromosuccinic Acids”; Journal of the Chemical Society; 105:2879-2887 (1914).
Gawronski, J., et al.; “Factors Affecting Conformation of IR,R)-Tartaric Acid Ester, Amide and Nitrite Derivatives, X-Ray Diffraction, Circular Dichroism, Nuclear Magnetic Resonance and Ab Initio Studies”; Tetrahedron; 53(17):6113-6144 (1997).
Giordano, C., et al.; “First Asymmetric Synthesis of Enantionmerically Pure (1 R.25)-(-)- (1,2-Epoxypropyl)phosphonic Acid (Fosfomycin)”; J. Organic Chemistry, 54(6):1470-1473 (1989).
International Search Report for International Application No. PCT/US2005/01931 dated May 8, 2006.
International Search Report for International Application No. PCT/US2006/045773 dated Apr. 27, 2007.
Abstract of Koenig S., et al.; “Synthese Von N-Tert-Alkylglyoxysaeureamiden”; Synthesis, Georg Thieme Vertag, Stuttgart; pp. 1233-1234 (1993).
Lu, L.D.-L., et al.; “Two new asymmetric Epoxidation Catalysts. Unusual Stoichiometry and Inverse Enantiofacial Selection”; J. Organic Chemistry, 49(4):728-731 (1984).
Massicot, F., et al.; “Solvent-Free Synthesis of Tartramides Under Microwave Activation”; Synthesis; (16):2441-2444 (2001).
Abstract of K. Rehse, et al.; “Antiaggregatorisch und anticoagulante Eigenschaften von Oligoaminen, 6. Mitt.: Oligohydroxyalkandiamine” Archiv Der Pharmazie; 320: 1155-1161 (1987).
Wang, Ruo, et al.; “A Search for Pyrophosphate Mimics for the Development of Substrates and Inhibitors of Glycosyltransferases”; Bioorganic & Medicinal Chemistry; 5(4):661-672 (1997).
Xu, Ping, et al.; “Synthesis of a Peptidomimetic HCMV Protease Inhibitor Library”; Synthesis; (8):1017-1026 (2002).
Notice of Allowance for U.S. Appl. No. 11/142,601 mailed May 6, 2009.
Notice of Allowance for U.S. Appl. No. 11/605,927 mailed Feb. 24, 2009.
Madison Vincent S.
Mansoor Umar Faruk
Reddy Panduranga A.
Siddiqui M. Arshad
Banerjee Krishna G.
Kosack Joseph R
McKown Jeremy
Schering Corporation
Shiao Rei-Tsang
LandOfFree
Compounds for the treatment of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of inflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114548